BCMA-targeted CAR-T Cell Therapy Market Projected to Expand at 25.0% CAGR by 2031 | Bristol-Myers Squibb (Abecma), CARsgen

Los Angeles, United State: A newly published report titled "Global BCMA-targeted CAR-T Cell Therapy Market Insights, Forecast 2025 to 2031" by QY Research throws light on the industry dynamics and current and future trends that play a key role in determining the business expansion. The BCMA-targeted CAR-T Cell Therapy report also highlights the key driving factors and restraints that are impacting the growth. For a comprehensive understanding, the professionals have reviewed the regulatory scenario, market entry strategies, best industry practices, pricing strategy, technology landscape, and consumption, sales, and demand outlook.

The global BCMA-targeted CAR-T Cell Therapy market was valued at US$ 1381 million in 2024 and is anticipated to reach US$ 6.87 billion by 2031, witnessing a CAGR of 25.0% during the forecast period 2025-2031.

Download Exclusive PDF Sample: (Including Full TOC, Data Tables, Visual Charts) @ https://qyresearch.in/request-sample/pharma-healthcare-global-bcma-targeted-car-t-cell-therapy-market-insights-industry-share-sales-projections-and-demand-outlook-2025-2031

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. Currently available CAR-T cell therapy products are divided into CD19 targets and BCMA targets. BCMA stands for B - cell maturation antigen. It is a protein that is found on the surface of plasma cells, which are abnormal cells that multiply uncontrollably in multiple myeloma, a type of blood cancer. By targeting BCMA, the CAR - T cell therapy aims to specifically attack the cancer - causing plasma cells.

Major players: The BCMA-targeted CAR-T cell therapy market presents a highly concentrated duopoly. In 2024, the global market CR2 index exceeded 98%. The main products are Carvykti (Cedacion) jointly developed by Legend Biotech and Johnson & Johnson and Abecma of Bristol-Myers Squibb. Among them, Carvykti continues to expand its market leadership with significant clinical advantages, and its global sales in 2024 increased by 93% year-on-year. In contrast, Abecma's sales in the current period decreased by about 14% year-on-year due to intensified market competition and product iteration pressure.

Leading players of the global BCMA-targeted CAR-T Cell Therapy market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global BCMA-targeted CAR-T Cell Therapy market. Furthermore, the report offers two separate market forecasts - one for the production side and another for the consumption side of the global BCMA-targeted CAR-T Cell Therapy market. It also provides useful recommendations for new as well as established players of the global BCMA-targeted CAR-T Cell Therapy market.

Featured Companies: -

Nanjing Legend Biotechnology/J&J (Carvykti)
Bristol-Myers Squibb (Abecma)
CARsgen
Nanjing Iaso Biotherapeutics

Market Trends: The BCMA CAR - T cell therapy market is in a phase of rapid growth. The reasons for this growth are two - fold. Firstly, there is a large population of patients with multiple myeloma, and there are many unmet medical needs. Secondly, this therapy has demonstrated good efficacy and has been recognized by the market. With the maturation of technology and market promotion, it is expected that the market will maintain a high growth rate in the coming years.

Expansion of Indications: Currently, BCMA CAR - T cell therapy is mainly used for the treatment of relapsed or refractory multiple myeloma. With the deepening of research, its indications are expected to be broadened. Pre - clinical and clinical trials are exploring its application in other hematological malignancies, such as certain types of leukemia and lymphoma. If successful, this will greatly expand the market size, bring hope to more patients, and inject new impetus into the growth of the therapy market.

Changing Competitive Landscape:The market competition is becoming increasingly fierce. In addition to the already - launched products such as Ciltacabtagene Autoleucel (Carvykti) and Idecabtagene Vicleucel (Abecma), many pharmaceutical companies are actively deploying and researching BCMA CAR - T products. New entrants may change the existing competitive landscape with innovative technologies or better cost control.

High - Cost Constraints: The research, development, and production processes of BCMA CAR - T cell therapy are complex, involving multiple high - cost links such as cell collection, gene editing, and cell culture, resulting in high product prices. This makes it difficult for many patients to afford, limiting the accessibility of the therapy and, to a certain extent, hindering the rapid expansion of the market. How to reduce costs so that more patients can benefit is an important challenge faced by the entire industry.

Safety Risks:Although this therapy has achieved remarkable results in clinical applications, there are still certain safety risks, such as cytokine release syndrome (CRS) and neurotoxicity. These adverse reactions may have a serious impact on the health of patients and even endanger their lives.

Why This Report is a Must-Have -

> Historical Analysis (2020-2024) & Forecasts (2025-2031): Gain a clear understanding of market trends and future growth potential.

> Comprehensive Market Segmentation: Detailed breakdown by Type, Application, and Region to identify lucrative opportunities.

> Competitive Landscape: Insights into key players, their market share, and strategic developments like mergers, acquisitions, and expansion plans.

> Drivers & Restraints: Understand the factors shaping the market's growth and the challenges that could impact your strategy.

> Expert Opinions & Market Dynamics: Benefit from expert analysis to navigate market risks and capitalize on emerging trends.

Detailed of BCMA-targeted CAR-T Cell Therapy Market Segmentation: -

Segmentation By Type :-

Abecma
Carvykti
Others

Segmentation By Application : -

Hospital
Oncology Clinic

BCMA-targeted CAR-T Cell Therapy Market Regional Insights -

United States

-Canada
-Mexico
-Brazil

APAC

-Japan
-South Korea
-China
-ASEAN
-India

EMEA

-Europe
-Middle East
-Africa

Request for Pre-Order Enquiry On This Exclusive Report @ https://qyresearch.in/pre-order-inquiry/pharma-healthcare-global-bcma-targeted-car-t-cell-therapy-market-insights-industry-share-sales-projections-and-demand-outlook-2025-2031

What You'll Gain from This Report -

> In-Depth Regional Analysis: Explore market potential across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

> Competitive Intelligence: Profiles of key players, including their sales, revenue, product portfolios, and recent developments.

> Market Dynamics: Understand the latest trends, driving factors, and risks impacting the industry.

> Actionable Insights: Make informed business decisions with data-driven strategies and forecasts.

How Can the Research Study Help your Business?

(1) The information presented in the BCMA-targeted CAR-T Cell Therapy report helps your decision makers to become prudent and make the best business choices.

(2) The report enables you to see the future of the global BCMA-targeted CAR-T Cell Therapy market and accordingly take decisions that will be in the best interest of your business.

(3) It offers you a forward-looking perspective of the global BCMA-targeted CAR-T Cell Therapy market drivers and how you can secure significant market gains in the near future.

(4) It provides SWOT analysis of the global BCMA-targeted CAR-T Cell Therapy market along with useful graphics and detailed statistics providing quick information about the market's overall progress throughout the forecast period.

(5) It also assesses the changing competitive dynamics of the global BCMA-targeted CAR-T Cell Therapy market using pin-point evaluation.

This BCMA-targeted CAR-T Cell Therapy Market Research Report Contains Answers to your following Questions -

(A) Which Manufacturing Technology is Used for BCMA-targeted CAR-T Cell Therapy? What Developments Are Going On in That Technology? Which Trends Are Causing These Developments?

(B) Who Are the Global Key Players in This BCMA-targeted CAR-T Cell Therapy Market? What's Their Company Profile, Their Product Information, and Contact Information?

(C) What Was Global Market Status of BCMA-targeted CAR-T Cell Therapy Market? What Was Capacity, Production Value, Cost and PROFIT of BCMA-targeted CAR-T Cell Therapy Market?

(D) What Is Current Market Status of BCMA-targeted CAR-T Cell Therapy Industry? What's Market Competition in This Industry, Both Company, and Country Wise? What's Market Analysis of BCMA-targeted CAR-T Cell Therapy Market by Taking Applications and Types in Consideration?

(E) What Are Projections of Global BCMA-targeted CAR-T Cell Therapy Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about Import and Export?

(F) What Is BCMA-targeted CAR-T Cell Therapy Market Chain Analysis by Upstream Raw Materials and Downstream Industry?

(G) What Is Economic Impact On BCMA-targeted CAR-T Cell Therapy Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends?

(H) What Are Market Dynamics of BCMA-targeted CAR-T Cell Therapy Market? What Are Challenges and Opportunities?

(I) What Should Be Entry Strategies, Countermeasures to Economic Impact, Marketing Channels for BCMA-targeted CAR-T Cell Therapy Industry?

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of BCMA-targeted CAR-T Cell Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Sales, revenue of BCMA-targeted CAR-T Cell Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

About Us:

QYResearch established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Contact Us:

Arshad Shaha | Marketing Executive

QY Research, INC.
315 Work Avenue, Raheja Woods,
Survey No. 222/1, Plot No. 25, 6th Floor,
Kayani Nagar, Yervada, Pune 411006, Maharashtra
Tel: +91-8669986909
Emails - arshad@qyrindia.com
Web - https://www.qyresearch.in

This release was published on openPR.